21-466 Phase II
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)
Search Cancer Clinical Trials
Mass General Brigham Cancer Institute offers patients access to a wide variety of
clinical trials of promising new therapies. Use the search tool to find open protocols
for your type of cancer.
53 results
22-323 Phase II
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
25-622 Phase II
A Phase 1/2 Trial of TER-2013 in Participants with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
25-855 Phase II
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, a Nectin4/Trop2 ADC, as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors
22-577 Phase II
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)
23-362 Phase II
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
17-028 Phase II
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
25-229 Phase II
A Phase 1/2a, Multicenter, First-in-Human, Open-Label Clinical Trial Evaluating MDX2001 Monotherapy in Patients with Advanced Solid Tumors
25-286 Phase II
A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
25-531 Phase I
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
Showing 1 - 10 of 53 results